Latest Conference Articles

January 14th 2014, 3:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of ramucirumab and paclitaxel resulted in a significant prolongation in survival and gains in quality of life when compared to paclitaxel alone for the second-line treatment of patients with metastatic gastric cancer.

January 14th 2014, 3:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Combining two specific anti-cancer vaccines, rather than administering one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase II study presented January 14.

January 14th 2014, 2:59pm

Gastrointestinal Cancers Symposium (ASCO GI)

An analysis of phase III, second-line data has shown that RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer.

December 16th 2013, 1:51pm

San Antonio Breast Cancer Symposium

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

December 16th 2013, 12:04pm

San Antonio Breast Cancer Symposium

Postneoadjuvant bisphosphonate therapy in women with residual invasive disease following chemotherapy for primary breast cancer does not improve clinical outcomes, according to an interim analysis of a large phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.

December 16th 2013, 10:12am

San Antonio Breast Cancer Symposium

Laura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

December 13th 2013, 4:18pm

San Antonio Breast Cancer Symposium

Andrew J. Brenner, MD, PhD, from the Cancer Therapy Research Center, discusses the link between obesity and breast cancer outcomes.

December 13th 2013, 3:36pm

San Antonio Breast Cancer Symposium

Julie R. Gralow, MD, from the Seattle Cancer Care Alliance, discusses the SWOG S0500 trial, which evaluated different therapies for patients with metastatic breast cancer who had elevated circulating tumor cell levels.

December 13th 2013, 3:23pm

San Antonio Breast Cancer Symposium

The first results from the novel the I-SPY 2 trial show encouraging possibilities for a veliparib/carboplatin combination therapy in TNBC.

December 13th 2013, 3:07pm

San Antonio Breast Cancer Symposium

Antiangiogenic therapy with ramucirumab, an investigational agent that binds to VEGFR-2, added to first-line docetaxel failed to delay the progression of HER2-negative metastatic breast cancer.

December 13th 2013, 1:16pm

San Antonio Breast Cancer Symposium

Switching chemotherapy based on level of elevated circulating tumor cells after one cycle of chemotherapy did not improve OS or PFS in women with metastatic breast cancer.

December 13th 2013, 12:50pm

San Antonio Breast Cancer Symposium

The addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response rates in patients with triple-negative breast cancer.

December 13th 2013, 11:33am

ASH Annual Meeting and Exposition

Combination treatment with idelalisib plus rituximab was associated with a >70% improvement in OS in patients with high-risk relapsed/refractory CLL.

December 13th 2013, 10:59am

San Antonio Breast Cancer Symposium

The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.

December 13th 2013, 10:59am

San Antonio Breast Cancer Symposium

Kristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

December 13th 2013, 10:10am

San Antonio Breast Cancer Symposium

Matthew J. Ellis, MD, PhD, from the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.

December 13th 2013, 10:03am

San Antonio Breast Cancer Symposium

Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 as a treatment for patients with breast cancer.

December 13th 2013, 9:43am

San Antonio Breast Cancer Symposium

In women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS),

December 13th 2013, 9:43am

San Antonio Breast Cancer Symposium

PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR). The lowest pCR was observed in HER2+/hormone receptor-positive (HR+), PIK3CA-mutated tumors.

December 13th 2013, 9:24am

San Antonio Breast Cancer Symposium

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.